Terms: = Breast cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400
1153 results:
1. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
2. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic breast cancer Treated With Abemaciclib: Data From the SCRUM-Japan cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors.
Magrath JW; Sampath SS; Flinchum DA; Hartono AB; Goldberg IN; Boehling JR; Savkovic SD; Lee SB
Cancer Res; 2024 May; 84(9):1426-1442. PubMed ID: 38588409
[TBL] [Abstract] [Full Text] [Related]
4. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract] [Full Text] [Related]
5. Aspongopus chinensis ach-miR-276a-3p induces breast cancer cell cycle arrest by targeting APPL2 to regulate the CDK2-Rb-E2F1 signaling pathway.
Cai R; Khan S; Chen X; Li H; Tan J; Tian Y; Zhao S; Yin Z; Liu T; Jin D; Guo J
Toxicol Appl Pharmacol; 2024 Mar; 484():116877. PubMed ID: 38431228
[TBL] [Abstract] [Full Text] [Related]
6. MYC induces CDK4/6 inhibitors resistance by promoting prb1 degradation.
Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
[TBL] [Abstract] [Full Text] [Related]
7. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract] [Full Text] [Related]
8. Drug-resilient cancer Cell Phenotype Is Acquired via Polyploidization Associated with Early Stress Response Coupled to HIF2α Transcriptional Regulation.
Carroll C; Manaprasertsak A; Boffelli Castro A; van den Bos H; Spierings DCJ; Wardenaar R; Bukkuri A; Engström N; Baratchart E; Yang M; Biloglav A; Cornwallis CK; Johansson B; Hagerling C; Arsenian-Henriksson M; Paulsson K; Amend SR; Mohlin S; Foijer F; McIntyre A; Pienta KJ; Hammarlund EU
Cancer Res Commun; 2024 Mar; 4(3):691-705. PubMed ID: 38385626
[TBL] [Abstract] [Full Text] [Related]
9. Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment.
Liu J; Cheng M; Xu J; Liang Y; Yin B; Liang J
Immunol Invest; 2024 Apr; 53(3):437-449. PubMed ID: 38314676
[TBL] [Abstract] [Full Text] [Related]
10. Encapsulated Rose Bengal Enhances the Photodynamic Treatment of Triple-Negative breast cancer Cells.
Uddin MMN; Bekmukhametova A; Antony A; Barman SK; Houang J; Wu MJ; Hook JM; George L; Wuhrer R; Mawad D; Ta D; Ruprai H; Lauto A
Molecules; 2024 Jan; 29(2):. PubMed ID: 38276623
[TBL] [Abstract] [Full Text] [Related]
11. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced breast cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract] [Full Text] [Related]
12. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q; Zhang J; Guo C; Wang M; Wang C; Yan Y; Sun L; Wang D; Zhang L; Yu H; Hou L; Wu C; Zhu Y; Jiang G; Zhu H; Zhou Y; Fang S; Zhang T; Hu L; Li J; Liu Y; Zhang H; Zhang B; Ding L; Robles AI; Rodriguez H; Gao D; Ji H; Zhou H; Zhang P
Cell; 2024 Jan; 187(1):184-203.e28. PubMed ID: 38181741
[TBL] [Abstract] [Full Text] [Related]
13. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
14. The dual activity of CaONPs as a cancer treatment substance and at the same time resistance to harmful microbes.
Awaad A; Olama ZA; El-Subruiti GM; Ali SM
Sci Rep; 2023 Dec; 13(1):22940. PubMed ID: 38135693
[TBL] [Abstract] [Full Text] [Related]
15. Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells.
Afsharzadeh M; Varshosaz J; Mirian M; Hasanzadeh F
Invest New Drugs; 2024 Feb; 42(1):89-105. PubMed ID: 38127209
[TBL] [Abstract] [Full Text] [Related]
16. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
17. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
18. Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (rb1) gene.
Palomar-Siles M; Yurevych V; Bykov VJN; Wiman KG
PLoS One; 2023; 18(11):e0292468. PubMed ID: 37917619
[TBL] [Abstract] [Full Text] [Related]
19. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors.
Lin FT; Liu K; Garan LAW; Folly-Kossi H; Song Y; Lin SJ; Lin WC
Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2307793120. PubMed ID: 37878724
[TBL] [Abstract] [Full Text] [Related]
20. [Inhibition of CD36 and Nogo-B expression inhibited the proliferation and migration of triple negative breast cancer cells].
Wang C; Han J; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4168-4188. PubMed ID: 37877398
[TBL] [Abstract] [Full Text] [Related]
[Next]
